Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Brent A. Neuschwander‐Tetri, Rohit Loomba, Arun J. Sanyal et al. · The Lancet · 2014 · 2.2K citations

Medicine, Internal Medicine, Pharmacology +14

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Chris Estes, Quentin M. Anstee, M. Arias et al. · Journal of Hepatology · 2018 · 2K citations · Full text

Medicine, Health Sciences, Epidemiologic Methods +16

A Regulatory Cascade of the Nuclear Receptors FXR, SHP-1, and LRH-1 Represses Bile Acid Biosynthesis

Bryan Goodwin, Stacey A. Jones, Roger R. Price et al. · Molecular Cell · 2000 · 1.9K citations · Full text

Life Sciences, Genetics, Molecular Biology +16

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

Gideon M. Hirschfield, Ulrich Beuers, Christophe Corpechot et al. · Journal of Hepatology · 2017 · 1.5K citations · Full text

Medicine, Clinical Sciences, Internal Medicine +13

Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c

Mitsuhiro Watanabe, Sander M. Houten, Li Wang et al. · Journal of Clinical Investigation · 2004 · 1.4K citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17